A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy (AVF4572).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2016
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 03 Oct 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Primary endpoint has been met. (Number of Patients with Progression Free Survival (PFS) at 16 weeks), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.